FDA EIR - Applied Therapeutics, Inc. - May 03, 2024

An FDA inspection of Applied Therapeutics, Inc., located in New York, NY, was conducted from April 29 to May 3, 2024. The inspection focused on the firm's role as a Commercial Sponsor-Monitor and Sponsor-Investigator, primarily for human and animal drugs, falling under the FDA's Bioresearch Monitoring (BIMO) regulatory framework. During the inspection, an FDA Form 483 was issued, indicating that observations were made regarding potential deviations from regulatory requirements. While specific violations are not detailed in this document, the issuance of a 483 mandates a response and corrective actions from the company. The district classified the inspection as "Correction Indicated" (CI) and "Voluntary Action Indicated" (VAI). The report has been forwarded to the Center for Drug Evaluation and Research (CDER) for final review and classification, meaning the ultimate regulatory decision and any further required actions are pending. Applied Therapeutics, Inc. is expected to address the issues outlined in the FDA Form 483.